For research use only.
Catalog No.S4125 Synonyms: 4-PBA, 4-Phenylbutyric acid
CAS No. 1716-12-7
Sodium phenylbutyrate is a salt of 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid.Sodium phenylbutyrate is a histone deacetylase inhibitor, used to treat urea cycle disorders.
Selleck's Sodium Phenylbutyrate has been cited by 13 publications
1 Customer Review
Representative images and quantitative analysis results of the transwell experiment. Notes: (A) Results of migration assay for DU145. (B) Results of invasion assay for DU145. (C) Results of migration assay for PC3. (D) Results of invasion assay for PC3. “*” Means significantly different from control group, P<0.05. Abbreviation: SPB, sodium phenylbutyrate.
OncoTargets and Therapy, 2016, 9:2825-2833.. Sodium Phenylbutyrate purchased from Selleck.
Purity & Quality Control
Choose Selective HDAC Inhibitors
|Description||Sodium phenylbutyrate is a salt of 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid.Sodium phenylbutyrate is a histone deacetylase inhibitor, used to treat urea cycle disorders.|
Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects. Phenylbutyrate significantly attenuates MPTP-induced depletion of striatal dopamine and loss of tyrosine hydroxylase-positive neurons in the substantia nigra.  Phenylbutyrate attenuates the expression of the apoptosis antagonist Bcl-X(L), the double-strand break repair protein DNA-dependent protein kinase, the prostate progression marker caveolin-1, and the pro-angiogenic vascular endothelial growth factor in prostate cancer cells. Phenylbutyrate is found to act in synergy with ionizing radiation to induce apoptosis in prostate cancer cells. 
|In vivo||Phenylbutyrate significantly extends survival and improved both the clinical and neuropathological phenotypes in G93A transgenic ALS mice. Phenylbutyrate administration ameliorates histone hypoacetylation observed in G93A mice and induced expression of nuclear factor-kappaB (NF-kappaB) p50, the phosphorylated inhibitory subunit of NF-kappaB (pIkappaB) and beta cell lymphoma 2 (bcl-2), but reduced cytochrome c and caspase expression. Phenylbutyrate acts to phosphorylate IkappaB, translocating NF-kappaB p50 to the nucleus, or to directly acetylate NF-kappaB p50.  Phenylbutyrate increases brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots in a transgenic mousemodel of Huntington's disease (HD). Phenylbutyrate increases mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum. |
|In vitro||Water||30 mg/mL (161.13 mM)|
|DMSO||8 mg/mL (42.96 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||4-PBA, 4-Phenylbutyric acid|
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT05019417||Recruiting||Drug: Glycerol Phenylbutyrate 1100 MG/ML||Monocarboxylate Transporter 8 Deficiency||Kaplan Medical Center|Weizmann Institute of Science||June 30 2021||Phase 2|Phase 3|
|NCT04937062||Recruiting||Drug: Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]||STXBP1 Encephalopathy With Epilepsy SLC6A1 Neurodevelopmental Disorder||Weill Medical College of Cornell University||March 1 2021||Early Phase 1|
|NCT04421677||Active not recruiting||Drug: Phenylbutyrate Oral Tablet||Inclusion Body Myositis|Sporadic Inclusion Body Myositis||University of Kansas Medical Center||August 20 2020||Phase 1|
|NCT02246218||Completed||Drug: RAVICTI||Urea Cycle Disorder||Horizon Therapeutics LLC|Horizon Pharma Ireland Ltd. Dublin Ireland||December 31 2014||Phase 4|
|NCT01096095||Withdrawn||Drug: Placebo|Drug: Sodium Phenylbutyrate||Spinocerebellar Ataxia Type 3||Hospital de Clinicas de Porto Alegre|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul Brazil||June 2010||Phase 2|
|NCT00947544||Completed||Drug: HPN-100|Drug: NaPBA||Urea Cycle Disorders||Horizon Pharma Ireland Ltd. Dublin Ireland||March 2010||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.